Scientific Sessions 2025  /  Moving the Needle: Valve Disease in the Young and Moderate Risk  /  How Low (Risk) Can You Go?: TAVR Should be reserved for high risk patients.
Logo

American Heart Association

  35
  0

Final ID:

How Low (Risk) Can You Go?: TAVR Should be reserved for high risk patients.

  • Ouzounian, Maral  ( Toronto General Hospital , Toronto , Ontario , Canada )
  • Thourani, Vinod  ( Piedmont Heart Institute , Atlanta , Georgia , United States )
  • Prendergast, Bernard  ( St Thomas' Hospital , London , United Kingdom )
  • Nazif, Tamim  ( Columbia University Medical Center , New York , New York , United States )
  • Mori, Makoto  ( Yale School of Medicine , New Haven , Connecticut , United States )
    • Author Disclosures:
    Maral Ouzounian: DO NOT have relevant financial relationships | Vinod Thourani: DO have relevant financial relationships ; Researcher:abbott vascular:Active (exists now) ; Researcher:Trisol:Active (exists now) ; Researcher:Laplace:Active (exists now) ; Researcher:Tricares:Active (exists now) ; Ownership Interest:Dasi Simulation:Active (exists now) ; Researcher:Jenavalve:Active (exists now) ; Researcher:medtronic:Active (exists now) ; Researcher:edwards lifesciences:Active (exists now) ; Researcher:boston scientific:Active (exists now) | Bernard Prendergast: DO NOT have relevant financial relationships | Tamim Nazif: No Answer | Makoto Mori: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Moving the Needle: Valve Disease in the Young and Moderate Risk

Monday, 11/10/2025 , 08:00AM - 09:15AM

Cardiovascular Seminar

More abstracts on this topic:
TEER for Moderate MR: Hold Your Horses!

Jorde Ulrich, Spinka Georg, Sugiura Atsushi

How Young is Too Young for TAVR?: TAVR should be the first choice, even for younger patients

Mack Michael, Makkar Raj

More abstracts from these authors:
EVOLVED Trial: Early SAVR or TAVR in Severe Asymptomatic Aortic Stenosis with Left Ventricular Fibrosis.

Mehran Roxana, Prendergast Bernard, Loganath Krithika, Dweck Marc

TRISCEND II 1-Year Outcomes (primary results at TCT)

Hahn Rebecca, Thourani Vinod, Kodali Susheel

You have to be authorized to contact abstract author. Please, Login
Not Available